Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 16.33% and Operating profit at -205.34% over the last 5 years
2
With a fall in Net Sales of -17.19%, the company declared Very Negative results in Mar 25
3
Risky -
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 18,182 Million (Large Cap)
NA (Loss Making)
NA
0.09%
-0.25
-1.13%
1.91
Revenue and Profits:
Net Sales:
686 Million
(Quarterly Results - Jun 2025)
Net Profit:
13 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.34%
0%
-0.34%
6 Months
-18.96%
0%
-18.96%
1 Year
-4.95%
0%
-4.95%
2 Years
-56.89%
0%
-56.89%
3 Years
-74.06%
0%
-74.06%
4 Years
-81.81%
0%
-81.81%
5 Years
-75.79%
0%
-75.79%
Walvax Biotechnology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
16.33%
EBIT Growth (5y)
-205.34%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.32
Sales to Capital Employed (avg)
0.37
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
11.25%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
13.84%
ROE (avg)
9.19%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.91
EV to EBIT
-78.43
EV to EBITDA
71.81
EV to Capital Employed
2.22
EV to Sales
6.26
PEG Ratio
NA
Dividend Yield
0.09%
ROCE (Latest)
-2.83%
ROE (Latest)
-1.13%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
686.10
828.40
-17.18%
Operating Profit (PBDIT) excl Other Income
91.90
213.50
-56.96%
Interest
0.50
3.00
-83.33%
Exceptional Items
-0.70
-17.20
95.93%
Consolidate Net Profit
12.60
219.20
-94.25%
Operating Profit Margin (Excl OI)
-19.90%
136.40%
-15.63%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -17.18% vs -37.54% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -94.25% vs -39.81% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,802.60
4,081.70
-31.34%
Operating Profit (PBDIT) excl Other Income
488.40
987.20
-50.53%
Interest
8.70
6.30
38.10%
Exceptional Items
-98.30
-235.40
58.24%
Consolidate Net Profit
174.40
511.30
-65.89%
Operating Profit Margin (Excl OI)
27.40%
160.20%
-13.28%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -31.34% vs -19.23% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -65.89% vs -45.50% in Dec 2023
About Walvax Biotechnology Co., Ltd. 
Walvax Biotechnology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






